Kolexia
Fagnoni-Legat Christine Pharmacien
Fagnoni-Legat Christine
Pharmacien
Hôpital Saint-Jacques de Besançon
Besançon, France
40 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Carcinomes Tumeurs du poumon Tumeurs du foie Carcinome hépatocellulaire Carcinome épidermoïde de la tête et du cou Carcinome pulmonaire non à petites cellules Carcinome pulmonaire à petites cellules Tumeurs fibreuses solitaires Syndrome de perfusion du propofol

Collaborateurs

Voir plus
Limat Samuel
Limat Samuel
Hôpital Saint-Jacques de Besançon, Besançon, France
Clairet Anne-Laure
Clairet Anne-Laure
Hôpital Saint-Jacques de Besançon, Besançon, France
Perrin Bonnot Sophie
Perrin Bonnot Sophie
Hôpital Saint-Jacques de Besançon, Besançon, France
Adotevi Olivier
Adotevi Olivier
Hôpital Jean-Minjoz, Besançon, France

Industries

Voir plus
Roche
3 collaboration(s)
Dernière en 2023
MSD
2 collaboration(s)
Dernière en 2022
Novartis
2 collaboration(s)
Dernière en 2022
VIATRIS SANTE
2 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
TERTIO: Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: a Proof of Concept Randomized Phase II Study (TERTIO - Prodige 82)
Essai Clinique (CHU Besançon)   10 novembre 2023
KS01.6.A UCPVAX-GLIO: A PHASE II TRIAL EVALUATING THE IMMUNOGENICITY AND EFFICACY OF AN ANTI-TELOMERASE VACCINE IN PATIENTS WITH NEWLY DIAGNOSED GBM
Abstracts from the 18th Meeting of the European Association of Neuro-Oncology   08 septembre 2023
Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82).
BMC cancer   29 juillet 2023
UCPVax: Anticancer Therapeutic Vaccination Using Telomerase-derives Universal Cancer Peptides in Metastatic Non Small Cell Lung Cancer : A Phase I/II Study
Essai Clinique (Invectys)   13 juillet 2023
VolATIL: A Phase II Study Evaluating the Interest to Combine UCPVax a CD4 TH1-inducer Cancer Vaccine and Atezolizumab for the Treatment of Human PapillomaVirus Positive Cancers
Essai Clinique (CHU Besançon)   25 mai 2023
Performance evaluation of the HPLC diode array and evaporative light scattering detection for the implementation of dose-banded gemcitabine infusion bags.
European journal of hospital pharmacy : science and practice   03 février 2023
Safety, Immunogenicity, and 1-Year Efficacy of Universal Cancer Peptide-Based Vaccine in Patients With Refractory Advanced Non-Small-Cell Lung Cancer: A Phase Ib/Phase IIa De-Escalation Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology   07 septembre 2022
Physicochemical and microbiological stability of insulin eye drops in an artificial tear vehicle used in the treatment of refractory neurotrophic keratopathy.
Journal francais d'ophtalmologie   29 juillet 2022
A Phase II Study Evaluating the Interest to Combine UCPVax, a Telomerase CD4 T 1-Inducer Cancer Vaccine, and Atezolizumab for the Treatment of HPV Positive Cancers: VolATIL Study.
Frontiers in oncology   19 juillet 2022
ATMP Environmental Exposure Assessment in European Healthcare Settings: A Systematic Review of the Literature.
Frontiers in medicine   01 décembre 2021